Stoke Therapeutics, Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2020-12-30

Reporting Person: Kaye Edward M. MD (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-30	Common Stock	M	10000	$0.60	Acquired	10000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-30	Employee Stock Option (right to buy)	$0.60	M	10000	Disposed	2028-04-02	Common Stock (10000)	Direct

Footnotes

F1: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.